APA (7th ed.) Citation

Reither, K., Katsoulis, L., Beattie, T., Gardiner, N., Lenz, N., Said, K., . . . Churchyard, G. J. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: A phase II, multi-centre, double-blind, randomized, placebo-controlled trial. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Reither, Klaus, et al. Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-infected Adults with CD4+ Lymphocyte Counts Greater than 350 Cells/mm3: A Phase II, Multi-centre, Double-blind, Randomized, Placebo-controlled Trial. Public Library of Science (PLoS).

MLA (9th ed.) Citation

Reither, Klaus, et al. Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-infected Adults with CD4+ Lymphocyte Counts Greater than 350 Cells/mm3: A Phase II, Multi-centre, Double-blind, Randomized, Placebo-controlled Trial. Public Library of Science (PLoS).